Company Filing History:
Years Active: 2009
Title: Innovator Jens ET Andersen's Patent on Water-Soluble Strontium Salts
Introduction: Jens ET Andersen is an accomplished inventor based in Vedbaek, Denmark. With a focus on developing innovative solutions for cartilage and bone conditions, he holds a notable patent that contributes to the pharmaceutical field. His work exemplifies the impact of scientific advancement in treating critical health issues.
Latest Patents: Jens ET Andersen's significant patent involves water-soluble strontium salts intended for the treatment and prophylaxis of cartilage and bone conditions. The patent describes compounds and pharmaceutical compositions that enhance the solubility of strontium, making it more effective for medical applications. Specifically, these compounds showcase a water-solubility range of approximately 1 g/l to 100 g/l at room temperature, emphasizing novel amino acid salts, such as strontium glutamate and strontium alpha-ketoglutarate. Furthermore, the invention includes improved methods for preparing strontium salt of glutamic acid, highlighting Andersen's commitment to innovation in pharmacology.
Career Highlights: Jens ET Andersen works with Osteologix A/S, where he applies his expertise to advance medical treatments that can significantly improve patient outcomes. His commitment to research and development is evident in his contributions to the field of pharmaceuticals, particularly in conditions affecting cartilage and bone health.
Collaborations: Throughout his career, Jens has collaborated with skilled professionals, including Christian Hansen and Henrik Nilsson. These partnerships reflect the collaborative spirit necessary for driving advancements in scientific research and innovation within the medical industry.
Conclusion: Jens ET Andersen stands out as a prominent inventor whose work on water-soluble strontium salts has the potential to revolutionize treatments for cartilage and bone conditions. Through his innovative solutions and collaborations at Osteologix A/S, he continues to contribute significantly to medical science, enhancing therapeutic options for patients in need.